Aztreonam
Monobactams
Sold as Cayston · Emblaveo
- Drug class
- Monobactams
- Availability
- See label
- Routes
- Inhalation
- Markets covered
- 3
- Products on record
- 9
Overview
Aztreonam is an active pharmaceutical ingredient in the Monobactams group (J01DF). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 6 | May 22, 2026 |
| EU European Union | EMA | 2 | March 9, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
6 products
Uses
The treatment of the following infections caused by susceptible aerobic Gram-negative micro-organisms: Urinary tract infections: including pyelonephritis and cystitis (initial and recurrent) and asymptomatic bacteriuria, including those due to pathogens resistant to the aminoglycosides, cephalosporins or penicillins.
Gonorrhoea: acute uncomplicated urogenital or anorectal infections due to beta-lactamase producing or non-producing strains of N. gonorrhoeae. 2 CCRF25302, 0001 Lower respiratory tract infections: including pneumonia, bronchitis and lung infections in patients with cystic fibrosis.
Bacteraemia/septicaemia. Meningitis caused by Haemophilus influenzae or Neisseria meningitidis. Since Aztreonam provides only Gram negative cover, it should not be given alone as initial blind therapy, but may be used with an antibiotic active against Gram positive organisms until the results of sensitivity tests are known.
Bone and joint infections. Skin and soft tissue infections: including those associated with postoperative wounds, ulcers and burns. Intra-abdominal infections: peritonitis. Gynaecological infections: pelvic inflammatory disease, endometritis and pelvic cellulitis.
EUEuropean Union· EMA
2 products
Uses
Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
How to take
CACanada· Health Canada
1 product
Uses
AND CLINICAL USE ........................................................................................................ 3 CONTRAINDICATIONS .............................................................................................................................
3 WARNINGS AND PRECAUTIONS ............................................................................................................ 4 ADVERSE REACTIONS ..............................................................................................................................
6 DRUG INTERACTIONS .............................................................................................................................. 9 DOSAGE AND ADMINISTRATION ........................................................................................................
10 OVERDOSAGE .......................................................................................................................................... 11 ACTION AND CLINICAL PHARMACOLOGY .......................................................................................
Drug interactions
Known interactions involving Aztreonam. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL514630236 · revised March 6, 2026
- [2]European Medicines Agency · EMEA/H/C/000996 · revised March 9, 2026
- [3]Health Canada (DPD) · 02329840 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.